GEMMA VIÑAS VILARÓ

Oncología de Precisión de Girona

Navarro-Sabaté, A, Font, R, Espinas, JA, Solà, J, Martínez-Soler, F, Gil-Gil, M, Viñas, G, Tibau, A, Borrell, M, Segui, M, Margelí, M, Servitja, S, Perez, C, Domenech, M, Nava, M, Marin, M, Gonzalez, S, Borràs, JM

Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?

Cancers, 2025, 17 dx.doi.org/10.3390/cancers17020200

Oncología de Precisión de Girona , Epidemiología descriptiva, genética y prevención del cáncer , Enfermedades Digestivas y Microbiota

Pla H, Felip E, Obadia V, Pernas S, Viñas G, Margelí M, Fort-Culillas R, Del Barco S, Sabaté N, Fort E, Lezcano C, Cirauqui B, Quiroga V, Stradella A, Gil Gil M, Esteve A, Recalde S

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26, 1748-1758 dx.doi.org/10.1007/s12094-024-03399-3

Oncología de Precisión de Girona

Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, García-Saenz JÁ, Pernas S, Martínez-Jañez N, Jiménez D, Adrover E, de Andrés R, Mourón S, Bueno MJ, Manso L, Viñas G, Alba E, Llombart-Cussac A, Cortés J, Tebar C, Roe DJ, Grant A, Watson A, Colomer R, Mouneimne G

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.

CLINICAL CANCER RESEARCH, 2024, 30, 5094-5104 dx.doi.org/10.1158/1078-0432.CCR-24-1518

Oncología de Precisión de Girona

Teruel I, Castellà E, Recalde S, Viñas G, Petit A, Trigueros M, Martínez-Balibrea E, Felip E, Bergamino M, Bernat-Peguera A, Cirauqui B, Quiroga V, Ferrando-Díez A, Pous A, López A, Boronat L, Soler G, Recuero J, Romeo M, Guillén P, Mesía R, Ballana E, Martínez-Cardús A, Margelí M

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 dx.doi.org/10.3390/ijms252212241

Oncología de Precisión de Girona , Epidemiología descriptiva, genética y prevención del cáncer

Clèries R, Ameijide A, Buxó M, Vilardell M, Martínez JM, Font R, Marcos-Gragera R, Puigdemont M, Viñas G, Carulla M, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM

Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2023, 20 dx.doi.org/10.3390/ijerph20010405

Epidemiología descriptiva, genética y prevención del cáncer , Oncología de Precisión de Girona

Clèries R, Buxó M, Vilardell M, Ameijide A, Martínez JM, Font R, Marcos-Gragera R, Puigdemont M, Viñas G, Carulla M, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM

No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 dx.doi.org/10.3390/ijerph19063605

Epidemiología descriptiva, genética y prevención del cáncer , Oncología de Precisión de Girona

Font R, Buxó M, Ameijide A, Martínez JM, Marcos-Gragera R, Carulla M, Puigdemont M, Vilardell M, Civit S, Viñas G, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM, Clèries R

Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred

SCIENTIFIC REPORTS, 2022, 12, 8097-8097 dx.doi.org/10.1038/s41598-022-12228-y

Oncología de Precisión de Girona

Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, Sanchez A, Rizzo G, Santoro A, Cortellini A, Perone Y, Chester J, Iglesias M, Betti M, Vincenzi B, Libertini M, Mazzoni F, Zoratto F, Berardi R, Guida A, Wuerstlein R, Loizidou A, Sharkey R, Aguilar Company J, Matas M, Saggia C, Chiudinelli L, Colomba-Blameble E, Galazi M, Mukherjee U, Van Hemelrijck M, Marin M, Strina C, Prat A, Pla H, Ciruelos EM, Bertuzzi A, Del Mastro L, Porzio G, Newsom-Davis T, Ruiz I, Delany MB, Krengli M, Fotia V, Viansone A, Chopra N, Romeo M, Salazar R, Perez I, d'Avanzo F, Franchi M, Milani M, Pommeret F, Tucci M, Pedrazzoli P, Harbeck N, Ferrante D, Pinato DJ, Gennari A

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13 dx.doi.org/10.1177/17588359211053416

Metabolismo y Cáncer , Oncología de Precisión de Girona

Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Journal of Clinical Medicine, 2019, 8 dx.doi.org/10.3390/jcm8122180

Metabolismo y Cáncer , Oncología de Precisión de Girona

Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

Aging-Us, 2019, 11, 2874-2888 dx.doi.org/10.18632/aging.101960

Directori

Publicacions

Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain

No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach

Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

Formulari de contacte

Conoce el IDIBGI!